New drug combo aims to help leukemia patients stop treatment
NCT ID NCT07108998
Summary
This study is testing whether adding a drug called epcoritamab to standard treatment can help patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve a deeper remission. The goal is to see if this combination can eliminate nearly all cancer cells, potentially allowing some patients to safely stop their medications. The trial will enroll 22 adults who have already responded partially to their current treatment but still have detectable disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.